Tryton Medical said yesterday it launched a post-approval study of its Tryton Side Branch Stent system designed for treating coronary artery disease. The side-branch stent is designed to be compatible with any conventional drug-eluting stent in the main vessel, and comes in sizes ranging from 2.5mm to 3.5mm, the Durham, N.C.-based company said. “Greater than 20% […]
Cerner Corp. (NSDQ:CERN) said yesterday that it named Brent Shafer to serve as chairman & CEO effective Feb. 1. Shafer previously served as CEO of Philips‘ (NYSE:PHG) North America business. Cerner’s co-founder Cliff Illig has been serving as interim CEO and chairman of the board since July last year. Illig said he plans to resume […]
Tryton Medical said today that its Side Branch Stent designed to treat coronary bifurcation lesions has been used in its 1st commercial procedure, performed by Dr. Martin Leon and Dr. Ajay Kirtane at the New York-Presbyterian Hospital . The side-branch stent is designed to be compatible with any conventional drug-eluting stent in the main vessel, and comes […]
Tryton Medical said today that it won pre-market approval from the FDA for its its side-branch stent for treating coronary bifurcation lesions and has already inked an exclusive U.S. distribution deal withCardinal Health (NYSE:CAH) subsidiary Cordis. The side-branch stent is designed to be compatible with any conventional drug-eluting stent in the main vessel, and comes in sizes […]
Tryton Medical raised $4 million in a new round of equity financing, according to an SEC filing posted this week. The Durham, N.C.-based vascular device developer has not yet stated how it plans to spend funds raised or the closing date for the round. Money in the round came from 8 unnamed sources, according to […]
St. Jude Medical (NYSE:STJ) said today that its newly acquired HeartMate PHP heart pump met its safety and efficacy endpoints in the Shield I trial used to back its CE Mark approval last summer. The results from Shield I’s 1st 30 patients led to the CE Mark nod in July. Today St. Jude said data from 46 subjects […]
Tryton Medical said yesterday that data from a post hoc analysis of a randomized clinical trial of its Tryton side branch stent for patients with coronary bifurcation lesions showed reductions in target vessel failure and improved side branch diameter. Results from the study were published in the journal Catheterization and Cardiovascular Interventions. The 289-patient post-hoc analysis […]
A pivotal clinical trial of Tryton Medical‘s side-branch stent, the largest ever conducted on coronary bifurcation lesions, failed to meet its primary endpoint for target vessel failure.
Tryton Medical said today that’s made an initial closing on a $20 million private equity round from existing and new investors.
Tryton Medical said it won CE Mark approval in the European Union for its side-branch stent to treat left main coronary artery disease.
Durham, N.C.-based Tryton already has European clearance for the side branch stent, but only for treating bifurcated large-vessel lesions. The new approval makes the device the only stent cleared in Europe for the left main indication, according to a press release.